AtCor Medical Pty Ltd Announces $1.5 Million in New Pharmaceutical Trial Contracts
Published: Dec 10, 2008
ITASCA, IL--(Marketwire - December 10, 2008) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressure and arterial stiffness noninvasively, today announced that it has signed new agreements to supply SphygmoCor systems and clinical trial support services to two leading international pharmaceutical companies. The minimum values of the contracts are $860,000 and $650,000 respectively. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor in the past six months to over $5.7 million.